GSA Capital Partners’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

GSA Capital Partners’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-37,452	Closed	-$56K	–	2069
2023 Q1	$56K	Buy	+37,452	New	+$50.4K	0.01%	1396
2022 Q2	–	Sell	-158,593	Closed	-$438K	–	1935
2022 Q1	$438K	Buy	158,593 +84,191	+113%	+$265K	0.06%	630
2021 Q4	$347K	Buy	74,402 +823	+1%	+$5.14K	0.04%	842
2021 Q3	$626K	Buy	73,579 +41,637	+130%	+$588K	0.06%	552
2021 Q2	$524K	Buy	31,942 +21,917	+219%	+$443K	0.06%	593
2021 Q1	$221K	Buy	10,025 +3,237	+48%	+$88.3K	0.04%	840
2020 Q4	$210K	Buy	+6,788	New	+$172K	0.03%	962

GSA Capital Partners's TCRR Position: Q2 2023 in Review

GSA Capital Partners sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 37,452 shares — an estimated $56K sold.

GSA Capital Partners first reported a position in TCRR in Q4 2020 and held it in 7 quarters. The position peaked at $626K in Q3 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

GSA Capital Partners reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
GSA Capital Partners sold 37,452 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $56K.
GSA Capital Partners first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 7 quarters.
GSA Capital Partners's TCR2 Therapeutics Inc. Common Stock position peaked at $626K in Q3 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on GSA Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.